Sensus Healthcare

Superficial Radiotherapy (SRT) offers a non-surgical option for treating non-melanoma skin cancer. With a cure rate of 98.9%, it can be the solution for patients who may not be candidates for surgery or prefer a treatment option that doesn’t impact their daily quality of life.

Learn more about SRT from Sensus Healthcare as an alternative to Mohs: https://sensushealthcare.com/alternative-mohs-surgery/

The reality: One in five Americans will be diagnosed with skin cancer by age 70. The majority of those diagnoses are non-melanoma skin cancers (basal cell and squamous cell carcinomas) which are highly treatable when caught early.

As diagnosis rates climb, so does the demand for non-surgical treatment options. That's where Superficial Radiotherapy (SRT) comes in.

CBS News recently featured Sensus Healthcare CEO Joe Sardano to discuss what the latest numbers mean for patients, dermatologists, and the future of non-invasive care.

👉 Watch the full CBS News segment here:

Skin cancer cases rising in the U.S., report says New data on skin cancer in the U.S. makes a stronger case for monitoring and preventative measures. Joseph Sardano, the CEO of Sensus Healthcare, joins CBS News with more details.